Health Care Equipment

Penumbra

Penumbra shareholders approve merger with Boston Scientific

Penumbra released FY2026 Q1 earnings on May 6 (EST), actual revenue USD 374.76 M (forecast USD 372.04 M), actual EPS USD 0.82 (forecast USD 1.0768)

Penumbra released FY2025 Q4 earnings on February 25 (EST), actual revenue USD 385.39 M (forecast USD 367.18 M), actual EPS USD 1.2003 (forecast USD 1.0663)

Penumbra released FY2025 Annual Earnings on February 25 (EST), actual revenue USD 1.404 B (forecast USD 1.384 B), actual EPS USD 4.52 (forecast USD 4.3087)

Boston Scientific Advises to Withdraw AXIOS Stent and Delivery Systems

Penumbra Analyst Ratings Upgraded, Target Price Increased

Wells Fargo Downgrades Penumbra's Rating to 'Hold' from 'Strong Buy'

Penumbra, Inc. Reports Q4 2025 Revenues Beat Expectations

Boston Scientific to Acquire Penumbra for $14.5 Billion

Penumbra Inc. reported 22% Q4 revenue growth, with full-year revenue reaching $1.4 billion

RBC Capital Analyst Reiterates Buy Rating on Penumbra

J.P. Morgan Maintains Buy Rating on Penumbra

David Rescott Maintains Buy Rating on Penumbra

Bellevue Group AG reduces its stake in Penumbra, Inc.

Qube Research & Technologies Acquires New Position in Penumbra in Q2

First Trust Advisors LP Increased Holdings in Penumbra, Inc.

Russell Investments Increases Stake in Penumbra, Inc.

Penumbra Inc. EVP Disposes of Common Stock

Penumbra Inc. Director Harpreet Grewal Reports Sale of Company Shares

American Century Companies Significantly Increased Its Holdings in Penumbra, Inc.

Micware

Silexion Therapeutics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Linkage Global

GCL Global

Jupiter Neurosciences

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

HCW Biologics

Arcadia Biosciences

SBIO

New York Life Investment Management LLC acquired a $999,000 stake in Penumbra, Inc. (NYSE:PEN), purchasing 3,213 shares in Q4. Other institutional investors also increased their positions. Penumbra's stock opened at $326.40, with a market cap of $12.84 billion. The company reported $0.82 EPS, missing estimates, but revenue rose 15.6% year-over-year. Analysts have mixed ratings, with an average target price of $361.33.

Market Beat

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares US Medical Devices

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Health Equip

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

ALPS Medical Breakthrough

KeyCorp

Evercore

ROYAL BANK OF CANADA

UBS Group AG

Citigroup

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

CITIGROUP INC 6.250 NON CUM SER II PFD WI

New York Life Investment Management LLC Takes $999,000 Position in Penumbra, Inc. $PEN

Radnor Capital Management LLC acquired 3,550 shares of Penumbra, Inc. (NYSE:PEN) valued at approximately $1.1 million during Q4, according to SEC filings. Other institutional investors have also increased their stakes in the company. Penumbra's stock has a consensus 'Hold' rating with an average target price of $361.33. Recent insider transactions include sales by Director Harpreet Grewal and CFO Maggie Yuen. As of now, 88.88% of the stock is owned by institutional investors.

Daiwa Securities Group Inc.

3,550 Shares in Penumbra, Inc. $PEN Bought by Radnor Capital Management LLC

Penumbra, Inc. (NYSE:PEN) has received a consensus rating of "Hold" from 17 analysts, with 14 recommending hold and 3 suggesting buy. The average 1-year price target is $361.33. Recent analyst reports include a hold rating from Wall Street Zen and a neutral rating from Robert W. Baird with a price target increase to $374. CFO Maggie Yuen and Director Harpreet Grewal recently sold shares, reducing their ownership. Institutional investors hold 88.88% of the stock. Penumbra's stock opened at $321.64, with a market cap of $12.65 billion and a P/E ratio of 74.11.

Wells Fargo

HSBC

HSBC HOLDINGS

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

HSBC 5xShortSG241213

HSBC Holdings Plc

Penumbra, Inc. (NYSE:PEN) Receives Consensus Rating of "Hold" from Analysts

Boston Scientific (BSX) is under scrutiny following new clinical data for its FARAPULSE PFA and WATCHMAN LAAC platforms, presented at Heart Rhythm 2026. Despite positive clinical results, the stock has seen a significant decline of 40.27% year-to-date. The company faces challenges due to the Penumbra acquisition, which is expected to dilute earnings and increase debt. Analysts suggest BSX is undervalued at a fair value of $98.90, but future growth depends on successful integration and market response. Investors are encouraged to assess the risks and opportunities in the current landscape.

Simplywall

Boston Scientific

Boston Scientific (BSX) Valuation Check After New Atrial Fibrillation And Stroke Prevention Data

Penumbra shareholders approved the merger with Boston Scientific during a special meeting on May 6, 2026. A quorum of 28,665,933 shares voted on three proposals, including the merger agreement, which received overwhelming support. The advisory compensation for executives was also approved, while the adjournment proposal was deemed unnecessary. The merger will make Penumbra a wholly owned subsidiary of Boston Scientific, pending regulatory approvals. Analysts currently rate Penumbra stock as a Hold with a price target of $350.00, citing strong financial performance but noting concerns over valuation and technical setup.

Tip Ranks

Penumbra Shareholders Approve Merger with Boston Scientific

Earnings Watch

Penumbra | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 374.76 M

Penumbra (PEN) is currently priced at approximately $325.33, but recent analysis suggests it may be overvalued by 80.4% based on a Discounted Cash Flow (DCF) model, which estimates its intrinsic value at $180.37. The stock has seen a 1.4% decline over the past week and a 1.1% decline over the past month, with year-to-date returns at 5.1%. Additionally, Penumbra's P/E ratio stands at 72x, significantly higher than the industry average of 23.6x, indicating a rich valuation. Investors are weighing growth potential against risks in the medical equipment sector.

Is Penumbra (PEN) Pricing In Too Much Growth After Recent Trial Developments

Boston Scientific Corp reported a strong first quarter for 2026, with revenue reaching $5.2 billion and diluted EPS of $0.9, marking an 11.6% increase year-over-year. Key drivers included growth in Electrophysiology, Interventional Cardiology, and Vascular Therapies. The company also improved its gross margin to 69.4% and engaged in strategic activities such as acquiring Nalu and announcing a deal with Penumbra, pending FTC review. Net income nearly doubled to $1.34 billion compared to the previous year.

TradingView

Boston Scientific Corp 1Q 2026: Revenue $5.2B, EPS $0.9— 10-Q Summary

Penumbra(PEN.US)